Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs KYMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Captures Overall Composite Edge (48.6 HOLD vs 47.2 HOLD), While KYMR Leads 4–1 on Growth & Valuation Pillars

CRSP Overall Winner 6-Pillar Tally: CRSP 1 – 4 KYMR (1 Tie) Matrix Metrics: CRSP 5 – 4 KYMR

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Kymera Therapeutics, Inc. (KYMR) on higher Unified Composite conviction (48.6/100 HOLD vs. 47.2/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while KYMR wins 4–1 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus KYMR at $124.79 (N/M Forward P/E, -396.0% operating margin).

  • Growth vs. Quality Trade-Off: CRSP earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. KYMR 47.2/100 HOLD) and 1.85β · 60% Vol risk profile, whereas KYMR leads top-line expansion (+466.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs KYMR
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80
KYMR NASDAQ
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
TTM Revenue $102M
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $124.63 · SMA50: $117.28

6-Pillar Scorecard Institutional Category Breakdown (CRSP 1 – 4 KYMR)

Columns: Metric · CRSP · KYMR
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 103.3x
2. Growth & Scale KYMR
Revenue Growth (YoY) +1325.1% +466.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $102M
Market Cap $4.1B $10.9B
3. Profitability & Quality KYMR
Gross Margin N/A N/A
Operating Margin -2058.6% -396.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -25.6% -27.3%
4. Balance Sheet & Cash Flow KYMR
Cash Generation (TTM) -$378M -$289M
Cash Flow Margin N/A N/A
Net Cash / Leverage $588M Net Debt (0.47x D/E) $297M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KYMR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 97.8% (52nd %ile) 129.6% (23rd %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (5) vs KYMR (4)
Institutional Metric CRSP KYMR Criterion Row Edge
Market Capitalization
Scale
$4.1B $10.9B Larger Scale KYMR
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% +466.4% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -396.0% Higher Margin KYMR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-25.6% -27.3% Higher ROE CRSP
52-Week Range Position
Momentum
1% ($40–$63) 78% ($62–$143) Stronger Trend KYMR
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 1.04β · 54% Vol Lower Realized Risk KYMR
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $102M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 103.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$289M ($297M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KYMR +36.64 pp
CRSP: -17.54% · KYMR: +19.1%
3M Horizon KYMR +26.14 pp
CRSP: -23.33% · KYMR: +2.81%
6M Horizon KYMR +73.0 pp
CRSP: -16.37% · KYMR: +56.63%
1Y Horizon KYMR +116.66 pp
CRSP: -20.54% · KYMR: +96.12%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue KYMR Revenue CRSP Op. Margin KYMR Op. Margin Margin Leader
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M $0M 16.1% -1438.5% CRSP
FY2020 $0M $30M -49295.5% -136.1% KYMR
FY2021 $910M $70M 40.8% -138.0% CRSP
FY2022 $0M $50M -56190.4% -344.4% KYMR
FY2023 $370M $80M -60.0% -210.6% CRSP
FY2024 $40M $50M -1250.4% -555.8% KYMR
FY2025 $0M $40M -18933.6% -891.1% KYMR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KYMR CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 129.6%
IV Percentile 23rd %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KYMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KYMR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.9B market capitalization and -396.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs KYMR Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Kymera Therapeutics, Inc. (KYMR) on higher Unified Composite conviction (48.6/100 HOLD vs. 47.2/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while KYMR wins 4–1 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus KYMR at $124.79 (N/M Forward P/E, -396.0% operating margin). Growth vs. Quality Trade-Off: CRSP earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. KYMR 47.2/100 HOLD) and 1.85β · 60% Vol risk profile, whereas KYMR leads top-line expansion (+466.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KYMR leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with KYMR at +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while KYMR shifted +33.3%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KYMR.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus KYMR (-27.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.